The Impact of Vitamin B12 Deficiency on Infant Gut Microbiota
NCT ID: NCT03365583
Last Updated: 2019-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2017-03-03
2017-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to compare the gut microbial composition of healthy term exclusively breastfed infants with or without vitamin B12 deficiency. We hypothesized that gut microbiome differs between vitamin B12 deficient and control infants; pathogenic bacteria are hypothesized to be higher, and beneficial bacteria to be lower in vitamin B12 deficient infants as compared to control.
An observational study in the Marmara University Pendik Research and Training Hospital well child outpatient clinic is conducted in 90 infants. Participants aged between 4 to 6 months who fulfill the inclusion criteria are enrolled.
Inclusion criteria are term birth (\>37 gestational weeks), birth weight \>2500 gr, absence of congenital anomalies, hemoglobin ≥10 g/dL, and exclusive breastfeeding.
Exclusion criteria include prematurity, low birth weight, intrapartum antibiotic use, current or previous use of infant formula, malnutrition, use of iron supplements, infant use of antibiotics, use of probiotics within the last 8 weeks before study entry, and introduction to solid foods.
Primary outcome measures:Microbial counts, and a comparison of type and abundance of species (predominant, pathogenic, and opportunistic bacteria, yeast, and parasites) between vitamin B12 deficient and sufficient subjects will be assessed.
Secondary outcome measures: Fecal bacterial communities will be assessed before and after treatment in a subgroup of infants.
Each stool sample is collected from cloth diapers, and placed in sterile collection tubes. Samples are kept at 4 C and in less than 5 hours, they are frozen at -80 C until further analysis. Specimens are transported on dry ice to the Diagen Inc for DNA extraction.
For the extraction protocol, QuickGene (Kurabo, North America) extraction device will be used.
The extracted DNA samples will be sent to Diversigen Inc (Houston, USA) for analysis. Fecal microbiota composition will be analyzed with 16S ribosomal ribonucleic acid (rRNA) sequencing.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Infant Micronutrition and Development
NCT05005897
Vitamin B12 Supplementation During Pregnancy on Cognitive Development
NCT03071666
Vitamin B12 Supplementation to Improve B12 Status and Child Development
NCT03258385
A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment
NCT04083560
How Many Patients Are in Need of Vitamin B12 Injections?
NCT00326833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The physiologic and neurologic consequences of micronutrient deficiencies have been addressed extensively. Although it is known that individuals with high bacterial loads in their small intestines tend to have low cobalamin status, less is known about its effects on the developing gut microbiota. It is suggested that early environmental factors influencing gut microbiota during this crucial developmental period can lead to long term consequences on health and disease. The data available is mostly limited to the effects of iron. The review of the literature has not yielded any study, which investigates the effects of vitamin B12 on the developing gut microbiota.
The study is conducted at Marmara University well child outpatient clinic. The clinic is hospital based and located in Pendik, Istanbul. The outpatient clinic provides well child care; and besides anthropometric measurements, infants are routinely screened for anemia at 4 to 6 months of age.
Ninety-two exclusively breastfed infants are approached for eligibility. Two infants are excluded due to prior antibiotic use and 90 infants are enrolled.
Fecal collection tubes are given to the parents of infants who fulfill the inclusion criteria during routine blood withdrawal. For the reporting, serum vitamin B12 \<203 pg/mL is considered as vitamin B12 deficiency, and ≥203 pg/mL as vitamin B12 sufficient.
Infants with vitamin B12 deficiency are treated with intramuscular vitamin b12 (hydroxycobalamin), 250-500 mcg twice weekly for a week, and then 500 mcg weekly for another 3 weeks. One month after the supplementation in the recommended dose, stools are recollected in a subgroup of subjects (n=11) with vitamin B12 deficiency.
Samples are kept at 4 C and in less than 5 hours, they are frozen at -80 C until further analysis.
Questionnaires are completed, antropometric measures are taken and fecal samples are transported on dry ice to the Diagen Inc for DNA extraction DNA extraction will be performed by Diagen Inc. For the extraction protocol, QuickGene (Kurabo, North America) extraction device will be used.
The extracted DNA samples will be sent to Diversigen Inc (Houston, USA) for 16S rRNA Gene V4 region sequencing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin B12 deficiency
No intervention will be administered for this study. Serum vitamin B12 \<203 pg/mL is considered as vitamin B12 deficiency.
Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual
No interventions assigned to this group
Vitamin B12 sufficient
Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
4 Months
6 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marmara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Perran Boran, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Marmara University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marmara University School of Medicine
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09.2016.137
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.